Breaking down translation barriers: Investigator's perspective

Science Translational Medicine

Volumn 6, Issue 252, 2014, Pages

  Staff, Nathan P ^a   Runge, Bethany Kinseth ^a   Windebank, Anthony J ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIORAL SCIENCE; FOOD AND DRUG ADMINISTRATION; FOOD SAFETY; FUNDING; GOOD MANUFACTURING PRACTICE; GOVERNMENT; HUMAN; INFORMATION SCIENCE; KNOWLEDGE MANAGEMENT; LEGAL ASPECT; MEDICAID; MEDICARE; NATIONAL HEALTH ORGANIZATION; NOTE; PEER REVIEW; PROCESSING; PROGRAM DEVELOPMENT; REGULATORY APPROVAL PROCESS; REIMBURSEMENT; RESEARCH; SOCIOLOGY; STRATEGIC PLANNING; TOXICOLOGY; TRANSLATIONAL RESEARCH; UNITED STATES; ECONOMICS; FINANCIAL MANAGEMENT; PERSONNEL;

HUMANS; RESEARCH PERSONNEL; RESEARCH SUPPORT AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84907290528     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008252     Document Type: Note

References (20)

1. R. C. Brownson, M. W. Kreuter, B. A. Arrington, W. R. True, Translating scientific discoveries into public health action: How can schools of public health move us forward? Public Health Rep. 121, 97-103 (2006).
2. J. M. Westfall, J. Mold, L. Fagnan, Practice-based research-" Blue Highways" on the NIH roadmap. JAMA 297, 403-406 (2007).
3. E. A. Balas, S. A. Boren, Managing clinical knowledge for healthcare improvement. Yearbook of Medical Informatics 2000. 2000, 65-70 (2000); www.ihi.org/resources/Pages/Publications/Managingclinicalknowledgeforhealthcareimprovement.aspx.
4. PCAST, "Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation" (Executive Office of the President, Washington, DC, 2012); www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fda-final.pdf.
5. Report of the Translational Research Working Group of the National Cancer Advisory Board, "Transforming Translation - Harnessing Discovery for Patient and Public Benefit" (National Cancer Institute, Bethesda, MD, 2007); www.ida.org/~/media/Corporate/Files/Publications/STPIPubs/transformingtranslationfinalreport.ashx.
6. D. Angius, H. Wang, R. J. Spinner, Y. Gutierrez-Cotto, M. J. Yaszemski, A. J. Windebank, A systematic review of animal models used to study nerve regeneration in tissue-engineered scaff olds. Biomaterials 33, 8034-8039 (2012).
7. U.S. Food and Drug Administration, "Advancing Regulatory Science at FDA" (2011); www.fda.gov/downloads/scienceresearch/specialtopics/regulatoryscience/ucm268225.pdf.
8. U.S. Food and Drug Administration, Clinical investigator training course. Fed. Regist. 76, 45577-45578; www.gpo.gov/fdsys/pkg/FR-2011-07-29/html/2011-19149.htm.
9. S. Olson, A. B. Claiborne, Accelerating the development of new drugs and diagnostics: Maximizing the impact of the cures acceleration network: Workshop summary (National Academies Press, Washington, DC, 2012), p. 115.
10. U.S. Department of Health and Human Services and FDA, IDEs for early feasibility medical device clinical studies, including certain first-in-human studies (2013); www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm279103.pdf.
11. E. Zerhouni, Medicine. The NIH Roadmap. Science 302, 63-72 (2003).
12. Committee to Review the Clinical and Translational Science Awards Program at the National Center for Advancing Translational Sciences, "The CTSA Program at NIH. Opportunities for Advancing Clinical and Translational Research" (Institute of Medicine, Washington DC, 2013); www.iom.edu/~/media/Files/Report%20Files/2013/CTSA-Review/CTSA-Review-RB.pdf.
13. National Institutes of Health, Neuro NEXT. The NEXT generation of neurologic treatments. NIH-Network for Excellence in Neuroscience Clinical Trials (2013); www.ninds.nih.gov/news-and-events/proceedings/20101217-NEXT.htm.
14. The Lancet Neurology, NeuroNEXT: Accelerating drug development in neurology. Lancet Neurol. 11, 119 (2012).
15. U.S. Food and Drug Administration, NIH and FDA announce collaborative initiative to fast-track innovations to the public (2010); www.nih.gov/news/health/feb2010/od-24.htm.
16. Center for Medicare and Medicaid Services, Medicare Clinical Trial Policies (2013); www.cms.gov/Medicare/Coverage/ClinicalTrialPolicies.
17. Medicare Advantage, Medicare advantage: Reforms needed to ensure access to clinical trials. J. Oncol. Pract. 5, 144-145 (2009).
18. M. E. Gurney, H. Pu, A. Y. Chiu, M. C. Dal Canto, C. Y. Polchow, D. D. Alexander, J. Caliendo, A. Hentati, Y. W. Kwon, H.-X. Deng, W. Chen, P. Zhai, R. L. Sufit, T. Siddique, Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775 (1994).
19. H. B. van der Worp, D. W. Howells, E. S. Sena, M. J. Porritt, S. Rewell, V. O'Collins, M. R. Macleod, Can animal models of disease reliably inform human studies? PLOS Med. 7, e1000245 (2010).
20. E. J. Sorenson, A. J. Windbank, J. N. Mandrekar, W. R. Bamlet, S. H. Appel, C. Armon, P. E. Barkhaus, P. Bosch, K. Boylan, W. S. David, E. Feldman, J. Glass, L. Gutmann, J. Katz, W. King, C. A. Luciano, L. F. McCluskey, S. Nash, D. S. Newman, R. M. Pascuzzi, E. Pioro, L. J. Sams, S. Scelsa, E. P. Simpson, S. H. Subramony, E. Tiryaki, C. A. Thornton, Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71, 1770-1775 (2008).